US Edition
StentIt launches first-in-human trial of bioresorbable stent to treat below-the-knee CLTI - Interventional News
Summary by Interventional News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
StentIt launches first-in-human trial of bioresorbable stent to treat below-the-knee CLTI - Interventional News
StentIt has announced the successful implantation of its Resorbable Fibrillated Scaffold (RFS). As part of the VITAL-IT 1 study, patients with chronic limb-threatening ischaemia (CLTI) below the knee have successfully been treated using the RFS implant. In this clinical procedure, revascularisation was achieved using an endovascular approach to restore blood flow to the foot. StentIt’s RFS device is a bioresorbable stent built from microfibers, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
